* Says Opdivo demonstrated objective response rate of 66.3%
in classical Hodgkin lymphoma patients
The post BRIEF-Bristol-Myers announces phase 2 data for Opdivo studies appeared first on NASDAQ.
Forex – financial instrument.Forex news
* Says Opdivo demonstrated objective response rate of 66.3%
in classical Hodgkin lymphoma patients
The post BRIEF-Bristol-Myers announces phase 2 data for Opdivo studies appeared first on NASDAQ.